Avalyn Pharma Inc. (AVLN) vs Nektar Therapeutics (NKTR)

Avalyn Pharma Inc. and Nektar Therapeutics are both Biotechnology companies. Avalyn Pharma Inc. and Nektar Therapeutics are of similar size ($1.2B and $1.2B). Avalyn Pharma Inc. has the higher net margin (0.00% vs −287.8%) and the lower return on invested capital (−102.6% vs −40.2%). Across the 11 metrics below, Avalyn Pharma Inc. leads on 6 and Nektar Therapeutics on 5.

Valuation

Metric AVLN NKTR Biotechnology median
P/E n/m n/m 10.60
P/S n/m 22.56 9.40
P/B 2.16 1.36 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 19.22 9.02
Earnings yield (357.99%) (17.99%) (32.88%)
Free cash flow yield (11.24%) (19.01%) (23.13%)

Profitability

Metric AVLN NKTR Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (257.80%) 0.00%
Net margin 0.00% (287.84%) 0.00%
Free cash flow margin 0.00% (428.72%) 0.00%
Return on equity 0.00% (35.75%) (51.96%)
Return on assets (43.95%) (24.12%) (46.06%)
Return on invested capital (102.61%) (40.20%) 0.00%

Growth

Metric AVLN NKTR Biotechnology median
Revenue growth (TTM) — (27.15%) 6.76%
EPS growth (last fiscal year) — (11.89%) 29.88%
Revenue growth, 5-year CAGR — (18.43%) 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AVLN NKTR Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 33.12 10.42 4.97
Net debt to EBITDA — 1.77 1.01

Dividend

Metric AVLN NKTR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AVLN NKTR Biotechnology median
Market cap 1.18b 1.23b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack